Institute of Nuclear Energy Research

Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan

Institute of Nuclear Energy Research, Atomic Energy Council

Tty Biopharm Company, Limited

Institute of Nuclear Energy Research Rocaec

Institute of Nuclear Energy Research, Taiwan

Te-Wei Lee

Shyh-Yi Chyi

Chih-Hsien Chang

Shiang-Rong Chang

Lie-Hang Shen

Zei-Tsan Tsai

Shu-Pei Chiu

Tian-Fu Huang

Ming-Hsin Li

Shui-Tein Chen

Su-Jung Chen

Yi-Jang Lee

Chun-Ying Huang

Ying-Kai Fu

Chien-Hong Lin

Gann Ting

Liang-Ting Lin

Ming-Der Yu

Wei-Lian Chen

Chang-Mau Shing

Kung-Tsung Wang

Feng-Yun Huang

Te-Jung Chen

Jem-Mau Lo

Kwo-Ping Chang

Yin-Mao Hsu

Kuo-Hsien Fan

Chia-Yu Yu

Wei-Chuan Hsu

Bo-Sian Lin

Charng-Feng Kao

Liang-Cheng Chen

Yao-Tsung Hsieh

Ming-Shiuan Wu

Henton Huang

Shu-Ling Chen

An-Jim Long

Hui-Lan Wu

The invention relates to a kit for preparation of target radiopharmaceuticals, a method of using the kit to prepare target radiopharmaceuticals and use of the target radiopharmaceuticals. The target radiopharmaceuticals comprise a radio-nuclear loading on liposome and inhibit the tumor growth and metastatic progression of head and neck cancer, lung cancer and brain cancer. The radiopharmaceuticals may be used for treating the mentioned cancers.

Kit for preparation of target radiopharmaceuticals and method of using it

An automated test apparatus for risk and integrity testing for pharmaceutical filtration membranes, including at least the following components: a liquid injection inlet, a pump, a fluid pressure gauge, a gas pressure gauge, a plurality of solenoid valves, a plurality of membranes, a gas pressure regulator valve, a pharmaceutical product bottle, and a bubble generation bottle. The automated test apparatus of the present invention is controlled by computer software in connection with an automatic pharmaceutical synthesis apparatus for automated testing. In use of the automated test apparatus of the present invention, it needs only to start the operating system of the automated test apparatus for membrane risk and integrity test after the completion of the automatic pharmaceutical synthesis. The membrane risk and integrity test can be accomplished in a short time by measuring pressures of gas and liquid with pressure gauges deposed online concurrently.

Automated test apparatus for testing risk and integrity of pharmaceutical filtration membranes and method thereof

The present invention relates to a method for preparingRe-labeled human serum albumin (HSA) microspheres byRe(I)-tricarbonyl ion. This radioactive particle can be subjected to radioembolization for liver tumor. In this method,Re(I)-tricarbonyl ion (Re(OH)(CO))) are employed as a precursor for directly labeling HSA microspheres withRe at appropriate temperature.

Method for making rhenium-186/188 labeled human serum albumin microspheres and kit for making the same and method for using the kit

The present invention relates to a volume-of-interest segmentation system for use with molecular imaging quantization, which includes: a set of template for segmentation of organ/anatomical region-of-interest, an animal size/weight/location calculator, an animal spine position calculator, and a texture analyzer. It can be used for saving time and reducing cost for segmentation of interested regions and increasing the precision of molecular image quantization.

Volume-of-interest segmentation system for use with molecular imaging quantization

This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of AsO, AsS, AsS, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i). This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the radioactive arsenic-containing compound and a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the treatment of tumors/cancers such as hematological malignancies and solid tumors.

Radioactive arsenic-containing compounds and their uses in the treatment of tumors

This invention relates a process for preparing octreotide and derivatives thereof. The starting material, Thr(ol)(tBu)-2-chlorotrityl resin is coupled with the various amino acids. The straight peptide-resin of D-Phe-Cys(Trt)-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(ol)(tBu)-2-chlorotrityl resin or D-Phe-Cys(Trt)-Tyr(tBu)-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(ol)(tBu)-2-chlorotrityl resin was obtained. Cleavage of the peptide from the resin was achieved by strong acid solution. The cleaved peptide reacted with charcoal to give disulfide-containing peptide of

Process for preparing octreotide and derivatives thereof

This invention is a novel synthesis of BCA-peptides (BCA: bifunctional chelating agents). In this method, the starting material--Fmoc-Thr(ol)-Terephthal-Acetal-Amide Resin is coupled with the various amino acids. The straight peptide-resin of D-Phe-Cys(Trt)-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(ol)-Terephtha l-Acetal-Amide Resin was obtained. This compound reacted with iodine to give disulfide-containing peptide resin of ##STR1## Cleavage of the peptide from the resin was achieved by TFA. The cleavaged peptide was protected by the reaction of octreotide with di-t-butyldicarbonate. BCA was coupled to the selectively protected octreotide. This product was obtained by reaction of protected BCA-peptides with TFA. The final product was labeled by radioisotope .sup.111 InCl.sub.3 for tumor imaging radiopharmaceuticals.

Method for synthesis of bifunctional chelating agents-peptides

Novel tumor imaging agents in which the dimercaptosuccinic acid was dissolved in phosphate buffer and labelled with radioisotope gallium. The product of gallium dimercaptosuccinate has been characterized by a variety of experiments including serum stability, biodistribution and imaging experiment. As the results, the compound of gallium dimercaptosuccinate has been confirmed as a novel radiopharmaceutical for tumor imaging agent.

Gallium dimercaptosuccinate as a novel tumor imaging agent

Growing community of inventors

Taipei, Taiwan

Te-Wei Lee